A downtrend has been apparent in Artivion (AORT) lately with too much selling pressure. The stock has declined 18.6% over the ...

Medical device company Artivion (NYSE:AORT) in Q4 CY2024 as sales rose 3.9% year on year to $97.31 million. The company’s ...

Artivion (NYSE:AORT – Get Free Report) had its target price reduced by equities research analysts at Stifel Nicolaus from $33 ...

Artivion, Inc. (NYSE:AORT – Get Free Report)’s stock price gapped down before the market opened on Tuesday following a dissappointing earnings announcement. The stock had previously closed at $27.85, ...

It's been a mediocre week for Artivion, Inc. ( NYSE:AORT ) shareholders, with the stock dropping 13% to US$25.42 in ...

Needham lowered the firm’s price target on Artivion (AORT) to $32 from $34 and keeps a Buy rating on the shares after its Q4 ...

Stifel lowered the firm’s price target on Artivion (AORT) to $30 from $33 and keeps a Buy rating on the shares after Q4 consensus sales ...

Reports Q4 revenue $97.3M, consensus $100.82M. “2024 was an excellent year for Artivion (AORT), marked by robust revenue and adjusted EBITDA ...

The Kennesaw, Georgia-based company said it had a loss of 39 cents per share. Earnings, adjusted for one-time gains and costs, were less than 1 cent on a per-share basis. The biological medical device ...

For the full year 2025, Artivion forecasts revenue between $420 million and $435 million, with the midpoint of $427.5 million falling below Wall Street's projection of $430.2 million. The revenue miss ...

KENNESAW, Ga. (AP) — KENNESAW, Ga. (AP) — Artivion, Inc. (AORT) on Monday reported a loss of $16.5 million in its fourth quarter. The Kennesaw, Georgia-based company said it had a loss of 39 ...